Remidio Launches Neubo 130 for AI-Enabled Retinal Imaging in Newborns

Built to assist clinicians in hospitals and NICUs, Neubo 130 integrates advanced optical engineering with edge AI to enable real-time ROP detection even without internet connectivity. 

Medtech startup Remidio Innovative Solutions has announced the launch of Neubo 130, an AI-powered ultra-widefield neonatal retinal imaging system designed to support precision diagnostics for Retinopathy of Prematurity (ROP) and other neonatal retinal conditions.

India records over three million premature births every year, which translates to nearly 15 million retinal examinations if each infant is screened as per clinical protocols. With limited ROP specialists available, technology-based screening is seen as a critical support tool to bridge the diagnostic gap.

Built to assist clinicians in hospitals and NICUs, Neubo 130 integrates advanced optical engineering with edge AI to enable real-time ROP detection even without internet connectivity. 

The system offers a 130° field of view, through-the-lens illumination, and light-shaping technology to ensure uniform brightness and improved peripheral visualization—key to detecting subtle retinal changes in newborns.

The device provides consistent peripheral detail, small-pupil imaging for pupils ≥3 mm, and instant bedside triage via offline AI that supports ROP and plus-disease screening. It also provides panoramic retinal views with fewer retakes through an auto-montage feature that aligns multiple gazes into a single composite image. The solution is telemedicine- and cloud-ready, enabling remote triage and referral for collaborative care.

“The launch of Neubo 130 marks a major step forward in neonatal eye care,” said Dr. Anand Sivaraman, CEO of Remidio. “This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard.’”

Dr. Anand Vinekar, Professor & Head, ROP Services at Narayana Nethralaya and Program Director of KIDROP, added, “With affordable imaging and AI-driven triage systems like Remidio’s Neubo 130, we can bring early and accurate ROP detection to even the most remote centers. The future of screening is simple, intelligent, and accessible – empowering every healthcare worker to protect a baby’s vision from the very first exam.”

With its lightweight design (below 500g), 2.4MP high-resolution imaging, and offline AI workflow, the device extends Remidio’s focus on making eye care accessible and scalable across tertiary hospitals and special newborn care units (SNCUs). The company currently operates in 55 countries and supports over 16 million screened patients globally.

Stay tuned for more such updates on Digital Health News